Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F10%3A10213246" target="_blank" >RIV/61989592:15110/10:10213246 - isvavai.cz</a>

Alternative codes found

RIV/00098892:_____/10:#0000398

Result on the web

—

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Thalidomide and bortezomib overcome the prognostic significance of proliferative index in multiple myeloma

Original language description

We analyzed proliferative index of myeloma plasmocytes (PC-PI) in a cohort of 217 patients with multiple myeloma (MM) treated with conventional chemotherapy and biological agents, thalidomide and bortezomib. In the whole group was a difference between overall survival (OS) favoring patients with PC-PI.lt.2,8% (median overall survival 30 vs 12 months) with a borderline significance (p=0,06). However, after approximately 40 months from diagnosis the curves merged, suggesting the influence of novel drugs.In patients treated with conventional chemotherapy only, the difference maintained significant even after 40 months (median overall survival 25 vs 10 months, p=0,015), whereas in the group treated with thalidomide and bortezomib was no difference, with medians over 39 months. Even patients with low PC-PI profited from the treatment with novel drugs. Presented results suggest that the treatment of MM with novel agents overcomes the prognostic significance of PC-PI and should be used in al

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NR9500" target="_blank" >NR9500: Angiogenesis, plasma cell kinetics, parameters of microenvironments of bone marrow and bone metabolism in monoclonal gammopathy of undetermined significance and initial phases of multiple myeloma</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2010

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Neoplasma

ISSN

0028-2685

e-ISSN

—

Volume of the periodical

57

Issue of the periodical within the volume

1

Country of publishing house

SK - SLOVAKIA

Number of pages

7

Pages from-to

—

UT code for WoS article

—

EID of the result in the Scopus database

—